Overview: Anti-PF4-Heparin IgG TestIntroduction: The Anti-PF4-Heparin IgG Test detects IgG antibodies to platelet factor 4-heparin to diagnose heparin-induced thrombocytopenia (HIT), causing clotting or bleeding. Following 2023 ASH guidelines, it uses an immunoassay for high sensitivity, aiding in coagulation screening. This test is critical for guiding diagnosis, treatment adjustments, and improving outcomes in coagulation for patients on heparin therapy.
Other Names: HIT IgG Assay, Heparin-Induced Thrombocytopenia Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: HIT antibody testing began in the 1990s with heparin research. Immunoassays improved in the 2000s, enhancing diagnostic specificity.
Purpose: Diagnoses HIT, guides anticoagulation therapy, and monitors anti-PF4-heparin IgG in patients with clotting or bleeding on heparin.
Test Parameters: 1. Anti PF4-Heparin IgG
Pretest Condition: No fasting required. Collect serum, plasma, or saliva at any time. Report symptoms like clotting or bleeding, and list heparin exposure.
Specimen: 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document clotting, bleeding, or history of heparin use. Include current medications, especially anticoagulants, and recent surgeries.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for alternative anticoagulation.
Procedural Considerations: Uses an immunoassay to detect anti-PF4-heparin IgG antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Recent heparin exposure, improper sample handling, or non-HIT thrombocytopenia can affect results. False positives may occur in inflammatory states.
Clinical Significance: Positive anti-PF4-heparin IgG suggests HIT, prompting heparin cessation and alternative anticoagulation. Negative results may require functional HIT testing.
Specialist Consultation: Consult a hematologist for result interpretation and anticoagulation management.
Additional Supporting Tests: Platelet count, 4Ts score, or serotonin release assay to confirm HIT diagnosis.
Test Limitations: False positives may occur in non-HIT conditions. Functional assays are needed for confirmation.
References: ASH HIT Guidelines, 2023; Blood, Warkentin TE, 2022.
